Aquestive Therapeutics (AQST Quick QuoteAQST - Free Report) reported $10 million in revenue for the quarter ended June 2025, representing a year-over-year decline of 50.2%. EPS of -$0.14 for the same period compares to -$0.03 a year ago.

The reported revenue represents a surprise of -9.62% over the Zacks Consensus Estimate of $11.07 million. With the consensus EPS estimate being -$0.18, the EPS surprise was +22.22%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Aquestive Therapeutics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenues- Manufacture and supply revenue: $9.58 million compared to the $8.49 million average estimate based on four analysts. The reported number represents a change of +18% year over year.
• Revenues- License and royalty revenue: $0.84 million versus $2.09 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -92.5% change.
• Revenues- Co-development and research fees: $0.38 million versus $0.5 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -50% change.

View all Key Company Metrics for Aquestive Therapeutics here>>>

Shares of Aquestive Therapeutics have returned -2.7% over the past month versus the Zacks S&P 500 composite's +2.7% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.